<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="At this time, using available conventional therapeutics along with other" exact="treatment" post="options may be useful to fight COVID-19. In different"/>
 <result pre="In this study, characteristics of remdesivir and its usage for" exact="treatment" post="of COVID-19 are reviewed based on an electronic search"/>
 <result pre="processes. At this time, administering conventional therapeutics along with other" exact="treatment" post="options such as inflammation control, oxygen therapy and fluid"/>
 <result pre="may be valuable to treat the clinical symptoms of the" exact="infection" post="such as cough, fever and difficulty breathing.2 SARS-CoV-2 shares"/>
 <result pre="this review, the characteristics, activity and usage of remdesivir for" exact="treatment" post="of COVID-19 aere discussed. An electronic search was done"/>
 <result pre="unapproved drug remdesivir for management of suspected or laboratory-confirmed SARS-CoV-2" exact="infection" post="in adults and pediatric patients hospitalized with severe disease.15"/>
 <result pre="ECMO and cases not requiring invasive mechanical ventilation and/or ECMO," exact="treatment" post="courses are 10 days and 5 days, respectively. If"/>
 <result pre="continued for up to 5 additional days for a total" exact="treatment" post="course of up to 10 days.15 However, in a"/>
 <result pre="animal models. For example, using remdesivir for prophylaxis and early" exact="treatment" post="in a mouse model with SARS-CoV infection led to"/>
 <result pre="prophylaxis and early treatment in a mouse model with SARS-CoV" exact="infection" post="led to a decrease of the viral load in"/>
 <result pre="authors suggested remdesivir as a highly effective agent against SARS-CoV-2" exact="infection" post="in vitro.18 Information obtained from in vitro studies and"/>
 <result pre="monophosphate, ester and phosphoramidate prodrugs was compiled.21â€&quot;23 Results of data" exact="screening" post="showed that GS-441,524 (a 1Ê¹-CN modified adenosine C-nucleoside hit)"/>
 <result pre="reported.24 Ebola meningoencephalitis was diagnosed in a female nurse by" exact="detection" post="of Ebola virus RNA in the plasma and cerebrospinal"/>
 <result pre="superior survival rates compared with remdesivir. Hence, randomization to remdesivir" exact="treatment" post="was stopped.25 Interestingly, the rate of viral clearance in"/>
 <result pre="the controls. The severity of lung lesions in the therapeutic" exact="treatment" post="group was lower than that in the vehicle-treated animals."/>
 <result pre="and clinical information of the subjects, data on course of" exact="infection" post="and clinical care were interpreted. Seven of 12 patients"/>
 <result pre="laboratory clues of worsening in the second week of the" exact="infection" post="were hospitalized. Three hospitalized patients received investigational antiviral remdesivir"/>
 <result pre="basis to patients with severe COVID-19. Patients with confirmed SARS-CoV-2" exact="infection" post="and breathing oxygen support or receiving ambient air were"/>
 <result pre="was daily used in the remaining 9 days of the" exact="treatment" post="course. Among 53 patients included in the cohort study,"/>
 <result pre="remdesivir in patients with Covid-19. Patients were randomly divided into" exact="treatment" post="and placebo groups receiving remdesivir for up to 10"/>
 <result pre="multicenter, retrospective study of the effects of remdesivir in the" exact="treatment" post="of severe COVID-19 infections Recruiting France June 2020 NCT04302766"/>
 <result pre="France June 2020 NCT04302766 An intermediate-size patient population expanded access" exact="treatment" post="protocol for coronavirus disease 2019 (COVID-19) using remdesivir (RDV;"/>
 <result pre="moderate COVID-19 Suspended China April 27, 2020 NCT04323761 Expanded access" exact="treatment" post="protocol: remdesivir (RDV; GS-5734) for the treatment of SARS-CoV-2"/>
 <result pre="NCT04323761 Expanded access treatment protocol: remdesivir (RDV; GS-5734) for the" exact="treatment" post="of SARS-CoV-2 (CoV) infection Available â€&quot; â€&quot; NCT04410354 A"/>
 <result pre="protocol: remdesivir (RDV; GS-5734) for the treatment of SARS-CoV-2 (CoV)" exact="infection" post="Available â€&quot; â€&quot; NCT04410354 A phase 2, randomized, double-blind,"/>
 <result pre="different clinical trials are important first steps to develop efficient" exact="treatment" post="against COVID-19.41 Beigel et al32 published a randomized, placebo-controlled,"/>
 <result pre="LalondeT, XuS. Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoV."/>
 <result pre="al. Efficacy and safety of the nucleoside analog GS-441524 for" exact="treatment" post="of cats with naturally occurring feline infectious peritonitis. J"/>
 <result pre="phosphoramidate prodrug of a Pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the" exact="treatment" post="of Ebola and emerging viruses. J Med Chem. 2017;60(5):1648â€&quot;1661."/>
 <result pre="doi:10.1038/s41422-020-0282-032020029 19.de WitE, et al. Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infection. Proc"/>
 <result pre="its discovery and development leading to emergency use authorization for" exact="treatment" post="of COVID-19. ACS Cent Sci. 2020;6:672â€&quot;683.32483554 21.De ClercqE. Strategies"/>
 <result pre="2020;20(6):697â€&quot;706. doi:10.1016/S1473-3099(20)30200-032224310 32.BeigelJH, TomashekKM, DoddLE, et al. Remdesivir for the" exact="treatment" post="of Covid-19â€&quot;preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2007764"/>
 <result pre="U.S. National Library of Medicine Clinical Trials Registry. Adaptive COVID-19" exact="treatment" post="trial. Available from: https://clinicaltrials.gov/ct2/show/NCT04280705. Accessed 721, 2020. 37.collab: U.S."/>
</results>
